Format

Send to

Choose Destination
J Gerontol A Biol Sci Med Sci. 2018 Dec 8. doi: 10.1093/gerona/gly273. [Epub ahead of print]

Association between sphingolipids and cardiopulmonary fitness in coronary artery disease patients undertaking cardiac rehabilitation.

Author information

1
Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
2
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
3
Toronto Rehabilitation Institute, Toronto, Ontario, Canada.
4
Departments of Neurology and Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
5
Centre for Addiction and Mental Health, Toronto, ON, Canada.
6
Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
7
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
8
Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
9
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

Abstract

The long term benefits conferred by cardiac rehabilitation (CR) in those with CAD are strongly linked with an improvement in cardiopulmonary fitness. This study aimed to determine the association between peripheral sphingolipids and cardiopulmonary fitness in CAD subjects undertaking CR. Patients with CAD (n=100, mean age=64±6 years, 85% male, mean years of education=17±3 years) underwent 6 months of CR with blood collected at baseline, 3 and 6 months. Cardiopulmonary fitness was assessed by measuring peak oxygen uptake (VO2peak) at all time points. High performance liquid chromatography coupled electrospray ionization tandem mass spectrometry was used to quantify plasma sphingolipid concentrations. Cross-sectional and longitudinal associations between sphingolipids and VO2peak were assessed using linear regressions and mixed models respectively. Higher concentrations of sphingomyelin C18:1 (=-0.26, p=0.01), ceramides C16:0 (=-0.24, p=0.02), C18:0 (=-0.29, p=0.002), C20:0 (=-0.24, p=0.02) and C24:1 (=-0.24, p=0.01) and monohexylceramide C18:0 (=-0.23, p=0.02) were associated with poorer VO2peak at baseline. An improvement in VO2peak was associated with a decrease in sphingomyelin C18:1 (b=-10.09, p=0.006), ceramides C16:0 (b=-9.25, p=0.0003), C18:0 (b=-5.44, p=0.0003) and C24:1 (b=-2.46, p=0.006) and monohexylceramide C18:0 (b=-5.37, p=0.005). Specific long chain sphingolipids may be useful markers of fitness and response to exercise in CAD.

PMID:
30535238
DOI:
10.1093/gerona/gly273

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center